Drug
Bezuclastinib clinical trials
Also written CGT9486 and PLX9486.
- studies test it
- 3
- open now
- 2
- in phase 3
- 1
- first study started
- 2021
Keep track of what changes. Save the bezuclastinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Cogent Biosciences, Inc. (3)
Studies
Open first, then newest update. How each study uses bezuclastinib is read from its arms, and is right about nine times in ten.
Testing it · 3
- (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisRecruitingPhase 2Cogent Biosciences, Inc.NCT04996875Written as bezuclastinib
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsRecruitingPhase 3Cogent Biosciences, Inc.NCT05208047Written as CGT9486
- (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisActive, not recruitingPhase 2Cogent Biosciences, Inc.NCT05186753Written as Bezuclastinib Tablets (Formulation A)
Given in every arm · 1 — bezuclastinib is usual care beside what is tested
Codes
What other systems call bezuclastinib · ClinicalTrials.gg INT014521
- UNII (FDA) 2ROQ545LAGBEZUCLASTINIBOne source FDA
- NCI Thesaurus C121647BezuclastinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2ROQ545LAG | BEZUCLASTINIB | One source FDA |
| NCI Thesaurus | C121647 | Bezuclastinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.